Lomitapide
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 349 publications
Therapeutic targeting of ROCK reverses EMT in lung cancer cells by impeding TAZ in Hippo signalling pathway.
Journal: Molecular and cellular biochemistry
Published: August 06, 2026
New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.
Journal: Circulation research
Published: June 04, 2026
Drugs for hypercholesterolemia.
Journal: The Medical letter on drugs and therapeutics
Published: June 01, 2026
Computational Drug Repurposing Predicts FDA-Approved Drugs as Potential Inhibitors of Chikungunya Virus nsP2 Protease.
Journal: The journal of physical chemistry. B
Published: May 29, 2026
Current and Future Perspectives of LDL-C Lowering Therapies 2026.
Journal: Journal of atherosclerosis and thrombosis
Published: May 27, 2026
Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry.
Journal: Journal of clinical lipidology
Published: May 12, 2026
Lipoprotein(a) carries triglyceride species associated with incident cardiovascular disease.
Journal: Atherosclerosis
Published: April 27, 2026
Homozygous familial hypercholesterolemia (HoFH) in Canada.
Journal: Atherosclerosis
Published: March 20, 2026
The evaluation of plozasiran for the treatment of familial chylomicronemia syndrome.
Journal: Expert review of endocrinology & metabolism
Published: March 20, 2026
Lomitapide as a Novel Therapeutic Agent in Breast Cancer: Mechanism and Potential Implications.
Journal: Recent patents on anti-cancer drug discovery
Published: February 10, 2026
Loss of KLF15 expression characterizes proximal tubule injury in cisplatin-induced acute kidney injury: A multi-omics study.
Journal: Current research in toxicology
Published: January 14, 2026
Last Updated: 09/26/2026